972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial

Gérard Zalcman, A-C. Madroszyk Flandin, Olivier Molinier, C. Dayen, Thomas Egenod, D. Debieuvre, Sophie Beaucaire-Danel, A. Dixmier, E. Pichon, S. Galland Girodet, E. Giroux-Leprieur, N. Cloarec, Jacques Cadranel, Josiane Otto, P. Romand, Alexandra Langlais, Franck Morin, Martine Antoine, V. Westeel, A.C. Toffart